Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First RemissionAndrew H. Wei, Gail J. Roboz, Dominik Selleslag et al.|New England Journal of Medicine|2020Cited by 432
Erythropoietin, iron, and erythropoiesisLawrence T. Goodnough, Carlo Brugnara, Barry Skikne|Blood|2000Cited by 301
Erythropoietin, iron, and erythropoiesisLawrence T. Goodnough, Carlo Brugnara, Barry Skikne|Blood|2000Cited by 273
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional careHartmut Döhner, Hervé Dombret, Anna Dolnik et al.|Leukemia|2018Cited by 136
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First RemissionAndrew H. Wei, Gail J. Roboz, Hartmut Döhner et al.|Blood|2019Cited by 97